Paradromics

• ·Paradromics’s last known valuation is $300.1M (Nov 2023).
• ·It has raised $127.4M across 4 recorded rounds; the latest was Later Stage VC ($50.1M) in Mar 2023.
• ·Notable investors include FJ Labs, Mana Ventures, Gaingels, Capital Factory, Joyance Partners — 51 tracked in total.
• ·6 investment vehicles were formed to buy Paradromics shares in the last 12 months, reporting $12.9M sold to 141 investors, per SEC Form D filings.
• ·Paradromics has filed 7 Form Ds with the SEC since 2019, most recently Nov 2023 ($50.1M sold to 53 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 6 investment vehicles were formed to buy Paradromics shares, reporting $12.9M sold to 141 investors across 6 sponsors. Most recent filing Jun 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Developer of a brain-computer interface technology designed to record and interpret brain activity for medical use. The company's technology offers implantable neural interfaces, data processing software, and machine learning models to capture single-neuron signals, process large volumes of brain activity data, and convert those signals into usable outputs for medical applications, enabling patients with neurological conditions and clinical research teams to translate brain signals into actionable data for communication and therapeutic applications.

Sector

Healthcare

HQ

Austin, TX, United States

Founded

2015

Employees

98

Website

paradromics.com/

Ownership

Privately Held (backing)